Innoviva Inc. (INVA) agreed to repurchase of GSK's equity stake in Innoviva, constituting about 32 million shares, or 32% of the outstanding common stock, at $12.25 per shar for a total purchase price of $392 million.
The purchase price represents a 3% discount to the 5-day volume weighted average price of Innoviva's common stock.
Innoviva noted that GSK was its largest shareholder for many years and remains a key commercial partner.'
In Thursday regular trade, INVA was trading at $12.80 up $0.51 or 4.11%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.